Ipsen, a French pharma company focused on oncology, neuroscience and rare diseases, has appointed Mari Scheiffele as EVP and President of Specialty Care International.
Based in Boulogne, she will be reporting directly to David Loew, CEO, Ipsen, and serve on the Executive Leadership Team.
“Along with the ELT, we are very pleased to welcome Mari to Ipsen. Her diverse experience will be critical in developing our three key therapeutic areas, Oncology, Rare Disease and Neuroscience, by continuing to strengthen Ipsen’s international commercial presence in over 115 countries, excluding North America,” said Mr Loew.
“Mari also brings valuable capabilities in transformation which she built over the course of her previous roles at Novartis and McKinsey. We are looking forward to working closely with her.”
Ms Scheiffele brings 20 years of healthcare leadership experience, from across the industry, having worked in the US, Europe and in Japan.
She joins Ipsen from Novartis where she has been in both global strategic and country operational roles, first in Japan and then in the UK.
Most recently, she has been General Manager, Novartis Oncology UK & Ireland where with a focus on patient-centricity, evidence-based medicine, and partnership, she has driven a successful business transformation.
Prior to Novartis, she was a partner at McKinsey & Company in New York and in Switzerland in Pharmaceuticals and Medical Products.
The appointment is effective November 1 2021.
